A comparative study of influential factors correlating with early and late hypothyroidism after 131I therapy for Graves' disease

被引:7
|
作者
Wang Ren-fei [1 ]
Tan Jian [1 ]
Zhang Gui-zhi [1 ]
Meng Zhao-wei [1 ]
Zheng Wei [1 ]
机构
[1] Tianjin Med Univ, Gen Hosp, Dept Nucl Med, Tianjin 300052, Peoples R China
关键词
Graves' disease; I-131; therapy; hypothyroidism; effective half-life time; thyroid microsome antibody; TERM-FOLLOW-UP; RADIOIODINE TREATMENT; PROGNOSTIC-FACTORS; DRUG-THERAPY; HYPERTHYROIDISM; THYROTOXICOSIS;
D O I
10.3760/cma.j.issn.0366-6999.2010.12.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background I-131 therapy is recognized as the simplest, safest, least expensive, and most effective treatment, and accepted by more and more patients. However its curative effect is influenced by many factors, therefore there are some difficulties for doctors to establish individual treatment strategy. The aims of this study were to determine the incidence of early and late hypothyroidism after I-131 treatment for Graves' disease (GD) and to compare their correlation, to observe and analyze the influential factors and to understand the predictabilities of them. Methods Five hundred GD patients (144 males, 356 females; age (41.2+/-12.3) years) received I-131 treatment for the first time. The therapeutic procedure was carried out as the following: undergoing I-131 uptake test to obtain maximum of thyroid uptake value and effective half-life (EHL) time; estimating the thyroid's weight by ultrasonography; determination of thyroid hormones and correlative antibodies; pre-therapy physical examination; thyroid imaging; calculating I-131 therapeutic dosage; per os uptake of the determined I-131 dosage; follow-up appraisal of curative effect. The observing parameters included age, gender, thyroid weight, GD duration, condition of onset, state of disease, course of treatment, EHL time, maximum of thyroid uptake value, I-131 dosage and titer of correlative antibodies. We sorted out the data and used both univariate and multivariate analysis to evaluate them statistically. Results The incidence rates of early and late hypothyroidism were 33.2% and 6.6% respectively after I-131 treatment and approximately 22.2% cases of late hypothyroidism developed from early hypothyroidism. The influential factors of early hypothyroidism included course of GD, the highest thyroid uptake ratio of I-131, EHL time and thyroid microsome antibody (TMAb), etc. A multivariate analysis on late hypothyroidism showed that female patients, with recurrence after anti-thyroid drug treatment and higher thyroid weight, had lower possibility of late hypothyroidism after I-131 therapy. Conclusions The incidence of early hypothyroidism is higher than that of late hypothyroidism. The highest thyroid uptake ratio of I-131, EHL and TMAb will increase the possibility of early hypothyroidism, while GD course is the protective factor. Higher I-131 dosage, longer EHL and higher TMAb titer will also increase the possibility of late hypothyroidism. The multi-perspective and multi-factor analysis has the benefit to establish individualized treatment strategy. Chin Med J 2010;123(12):1528-1532
引用
收藏
页码:1528 / 1532
页数:5
相关论文
共 44 条
  • [1] Analysis of 131I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study
    Wei Zheng
    Tan Jian
    Zhang Guizhi
    Meng Zhaowei
    Wang Renfei
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (01) : 97 - 101
  • [2] Predictive factors for the efficacy of 131I therapy with formulated dosage calculation on Graves' disease
    Zheng, Hongbin
    Sun, Danyang
    Zhang, Qing
    Jia, Qiang
    Tan, Jian
    Jin, Jiahui
    Meng, Zhaowei
    Wang, Yan
    Xu, Ke
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2022, 25 (02) : 119 - 124
  • [3] TRANSIENT HYPOTHYROIDISM AFTER I-131 THERAPY FOR GRAVES-DISEASE
    GOMEZ, N
    GOMEZ, JM
    ORTI, A
    GAVALDA, L
    VILLABONA, C
    LEYES, P
    SOLER, J
    ARNAIZ, NG
    JOURNAL OF NUCLEAR MEDICINE, 1995, 36 (09) : 1539 - 1542
  • [4] Correlation Between TRAb and Early Onset Hypothyroidism After 131 I Treatment for Graves' Disease
    Song, Qi
    Fang, Zhouyu
    Wang, Shurong
    Liu, Zhihua
    Xiao, Wenjin
    Zong, Haijun
    Xie, Ying
    HORMONE AND METABOLIC RESEARCH, 2024, 56 (11) : 779 - 784
  • [5] A case report of 131I therapy for Graves' disease patient with hemiagenesis
    Liu, Xuehui
    Zhang, Jianping
    Meng, Zhaowei
    Yu, Hongxu
    Gao, Zhimin
    Li, Hongjun
    Liu, Na
    MEDICINE, 2019, 98 (08)
  • [6] Maximum Dose Rate Is a Determinant of Hypothyroidism After 131I Therapy of Graves' Disease but the Total Thyroid Absorbed Dose Is Not
    Krohn, Thomas
    Haenscheid, Heribert
    Mueller, Berthold
    Behrendt, Florian F.
    Heinzel, Alexander
    Mottaghy, Felix M.
    Verburg, Frederik A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (11) : 4109 - 4115
  • [7] Influence of Glucocorticoid Therapy on intratherapeutic Biodistribution of 131I Radioiodine Therapy in Graves' Disease
    Halstenberg, Jorg
    Kranert, Wolfgang Tilman
    Korkusuz, Hudayi
    Mayer, Amelie
    Ackermann, Hanns
    Grunwald, Frank
    Happel, Christian
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (02): : 43 - 49
  • [8] Prognostic factors analysis for a calculated dose of 131I therapy in Graves' disease in China
    Zhao, Wan-Jun
    Lv, Qing-Guo
    Fei, Yuan
    Zhao, Zhen
    Zhang, Yu-Wei
    GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2019, 178 (1-2) : 9 - 18
  • [9] Cancer Risk in Graves Disease with Radioactive 131I Treatment: A Nationwide Cohort Study
    Kim, Kyeong Jin
    Choi, Jimi
    Kim, Kyoung Jin
    Song, Eyun
    Yu, Ji Hee
    Kim, Nam Hoon
    Yoo, Hye Jin
    Seo, Ji A.
    Kim, Nan Hee
    Choi, Kyung Mook
    Baik, Sei Hyun
    Kim, Sin Gon
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (05) : 693 - 699
  • [10] Predictive Factors of Outcomes in Personalized Radioactive Iodine (131I) Treatment for Graves' Disease
    Liu, Min
    Jing, Danqing
    Hu, Jingsheng
    Yin, Shinan
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 348 (04) : 288 - 293